The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism

This study has been completed.
Unilever R&D
Information provided by:
University of Copenhagen Identifier:
First received: August 21, 2007
Last updated: February 6, 2009
Last verified: February 2009

The aim of this study is to elucidate the role of specific catechins, a mixture of catechins and caffeine in relation to weight control with particular emphasis on energy metabolism and fat oxidation.

Condition Intervention
Dietary Supplement: green tea
Dietary Supplement: Mix of catechins and caffeine
Dietary Supplement: EGCG
Dietary Supplement: EGC
Dietary Supplement: Caffeine
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism in Man

Resource links provided by NLM:

Further study details as provided by University of Copenhagen:

Primary Outcome Measures:
  • fat oxidation [ Time Frame: november 2007 ]

Secondary Outcome Measures:
  • appetite [ Time Frame: november 2007 ]

Enrollment: 15
Study Start Date: November 2005
Study Completion Date: February 2006
Arms Assigned Interventions
Experimental: 1
Active treatment A
Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: Mix of catechins and caffeine
3 tablet a day
Experimental: 2
Active treatment B
Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: EGCG
3 tablets a day
Other Name: epigallocatechin gallate
Experimental: 3
Active treatment C
Dietary Supplement: green tea
different catechin combinations
Dietary Supplement: EGC
3 tablets a day
Other Name: Epigallocatechin
Active Comparator: 4
Positive control
Dietary Supplement: Caffeine
3 tablets a day
Placebo Comparator: 5
Dietary Supplement: Placebo
3 tablets a day

  Show Detailed Description


Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy men
  • Age 18-40 years
  • BMI 18,5-25 kg/m2

Exclusion Criteria:

  • Diabetes or any other endocrinological disease
  • Hypertensive medication
  • Increased Blood Pressure > 140/85
  • Hyperlpidimia
  • Chronic disease (i.e. HIV)
  • Use of any diet supplements including vitamins (during and 3 months prior to the study).
  • High alcohol intake (>21 units a week)
  • High caffeine intake (>250 mg/day) or high catechin intake (>200 mg/day)
  • Smoking
  • Elite sports performer
  • Use of any regular medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00611416

Institute of Human Nutrition, The Royal Veterinary and Agricultrual University
Frederiksberg C, Denmark, 1958
Sponsors and Collaborators
University of Copenhagen
Unilever R&D
Study Chair: Arne Astrup, Proffessor Insitute of Human Nutrition
  More Information

No publications provided Identifier: NCT00611416     History of Changes
Other Study ID Numbers: (KF) 01 279421, Unilever
Study First Received: August 21, 2007
Last Updated: February 6, 2009
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Keywords provided by University of Copenhagen:
energy expenditure
fat oxidation

Additional relevant MeSH terms:
Epigallocatechin gallate
Anticarcinogenic Agents
Antimutagenic Agents
Antineoplastic Agents
Central Nervous System Agents
Central Nervous System Stimulants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Neurotransmitter Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Protective Agents
Purinergic Agents
Purinergic Antagonists
Purinergic P1 Receptor Antagonists
Therapeutic Uses processed this record on October 23, 2014